EP1071685A1 - Preparation de produits intermediaires des carbapenems catalysee au titane - Google Patents

Preparation de produits intermediaires des carbapenems catalysee au titane

Info

Publication number
EP1071685A1
EP1071685A1 EP99916629A EP99916629A EP1071685A1 EP 1071685 A1 EP1071685 A1 EP 1071685A1 EP 99916629 A EP99916629 A EP 99916629A EP 99916629 A EP99916629 A EP 99916629A EP 1071685 A1 EP1071685 A1 EP 1071685A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
alkyl
produce
hoc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99916629A
Other languages
German (de)
English (en)
Other versions
EP1071685A4 (fr
Inventor
Philip J. Pye
Paul J. Reider
Kai Rossen
Ralph P. Volante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9811297.2A external-priority patent/GB9811297D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1071685A1 publication Critical patent/EP1071685A1/fr
Publication of EP1071685A4 publication Critical patent/EP1071685A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation
    • C07D477/04—Preparation by forming the ring or condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Definitions

  • the present invention relates to a process for synthesizing l- ⁇ -methyl-2- hydroxymethyl carbapenem intermediates. Generally the carbapenems are substituted at the 2-position. The intermediate compounds are included as well. European applications 0330108, 0102239, 0212404, 0695753 and 0476649 disclose methods for synthesizing various antibiotic derivatives.
  • carbapenems are useful against gram positive microorganisms, especially methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant Staphylococcus epidermidis (MRSE), and methicillin resistant coagulase negative Staphylococci (MRCNS). These antibacterials thus comprise an important contribution to therapy for treating infections caused by these difficult to control pathogens. There is an increasing need for agents effective against such pathogens (MRSA/MRCNS) which are at the same time relatively free from undesirable side effects.
  • MRSA methicillin resistant Staphylococcus aureus
  • MRSE methicillin resistant Staphylococcus epidermidis
  • MRCNS methicillin resistant coagulase negative Staphylococci
  • the invention describes a short and high yielding synthesis of protected l- ⁇ -methyl-2-hydroxymethyl substituted carbapenems as key intermediates for the synthesis of anti-MRSA carbapenem antibiotics.
  • the synthesis involves a highly diastereoselective addition of a titanium, zirconium or hafnium enolate of a suitably protected l-hydroxy-2- butanone derivative with 4-acyl-2-azetidinone.
  • the resulting derivatized 2-azetidinone product is obtained largely as a single diastereomer rather than a mixture.
  • the two chiral centers which are produced are of the correct absolute stereochemical
  • R 1 represents H or a suitable protecting group for an alcohol
  • R 2 represents a benzyl, C ⁇ alkyl or aryl
  • Y represents C ⁇ g alkyl, O, NH or S
  • X represents O, NH, or S comprising reacting a compound of formula 1:
  • R 1 is described above and R 4 represents C 1 . 15 alkyl, aryl or C 1 ar alkyl; with a compound of formula 3:
  • R 2 , X and Y are as previously defined in the presence of WZ 4 and an amine to produce a compound of formula 2, wherein W is a titanium, zirconium or hafnium metal and Z represents halo, sulfonate, alkoxy, aryloxy or combination thereof.
  • the present invention relates to a process for making protected l- ⁇ -methyl-2-hydroxymethyl substituted carbapenems which are key intermediates in the synthesis of anti-MRSA carbapenem antibiotics (such as those disclosed in USSN 08/825,786 filed on April 08, 1997, the teachings of which are hereby incorporated by reference).
  • the intermediates can be readily coupled to a wide range of functional groups (see USSN 08/825,786).
  • the invention is described herein in detail using the terms defined below unless otherwise specified.
  • alkyl refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 10 carbon atoms unless otherwise defined. It may be straight, branched or cyclic. Preferred alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t- butyl, cyclopentyl and cyclohexyl. When substituted, alkyl groups may be substituted with up to four substituent groups, selected from R ⁇ and R 1 , as defined, at any available point of attachment. When the alkyl group is said to be substituted with an alkyl group, this is used interchangeably with "branched alkyl group”.
  • Cycloalkyl is a species of alkyl containing from 3 to 15 carbon atoms, without alternating or resonating double bonds between carbon atoms. It may contain from 1 to 4 rings which are fused.
  • alkenyl refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. Preferred alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl.
  • alkynyl refers to a hydrocarbon radical straight or branched, containing from 2 to 10 carbon atoms and at least one carbon to carbon triple bond.
  • Preferred alkynyl groups include ethynyl, propynyl and butynyl.
  • Aryl refers to aromatic rings e.g., phenyl, substituted phenyl and the like as well as rings which are fused, e.g., naphthyl, phenanthrenyl and the like.
  • An aryl group thus contains at least one ring having at least 5 atoms, with up to five such rings being present, containing up to 22 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms or suitable heteroatoms.
  • the preferred aryl groups are phenyl, naphthyl and phenanthrenyl.
  • Aryl groups may likewise be substituted as defined.
  • Preferred substituted aryls include phenyl and naphthyl.
  • Aryl also refer to heteroaryl, which is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, or a poly cyclic aromatic group having 8 to 16 atoms, containing at least one heteroatom, O, S, S(O), S ⁇ 2 or N, in which a carbon or nitrogen atom is the point of attachment, and in which one or two additional carbon atoms is optionally replaced by a heteroatom selected from O or S, and in which from 1 to 3 additional carbon atoms are optionally replaced by nitrogen heteroatoms, said heteroaryl group being optionally substituted as described herein.
  • Examples of this type are pyrrole, pyridine, oxazole, thiazole and oxazine. Additional nitrogen atoms may be present together with the first nitrogen and oxygen or sulfur, giving, e.g., thiadiazole and the like.
  • aralkyl is intended to mean an aryl or heteroaralkyl moiety, as defined above, attached through a C ⁇ g alkyl linker, where alkyl is defined above.
  • alkyl is defined above.
  • aralkyls include, but are not limited to, benzyl, naphtylmethyl, phenylpropyl, 2-pyridylmethyl, 2-imidazolylethyl, 2-quinolinylmethy, 2-imidazolylmethyl and the like.
  • polycyclic heteroaromatics examples include benzopyrans, benzofurans, benzopyrroles, benzimidazoles, benzothiazoles, quinolines, purines, isoquinolines, benzopyrimidines, dibenzofurans, dibenzothiophenes, 1,8-naphthosultams,
  • heterocycle refers to a 5-16 membered cycloalkyl group (nonaromatic) with 1-4 rings, in which one of the carbon atoms in the ring is replaced by a heteroatom selected from O, S or N, and in which up to three additional carbon atoms may be replaced by heteroatoms.
  • heteroatom means O, S, S(O), S(0) 2 or N, selected on an independent basis.
  • Halogen and "halo" refer to bromine, chlorine, fluorine and iodine.
  • protecting groups for the compounds of the present invention will be recognized from the present application taking into account the level of skill in the art, and with reference to standard textbooks, such as Greene, T. W. et al. Protective Groups in Organic Synthesis Wiley, New York (1991). Examples of suitable protecting groups are contained throughout the specification.
  • R 1 and R 5 represent alcohol and carboxyl protecting groups, respectively.
  • Y may represent a protecting group for X, which in turn represents O or N.
  • These groups are generally removable, i.e., they can be removed, if desired, by procedures which will not cause cleavage or other disruption of the remaining portions of the molecule.
  • Such procedures include chemical and enzymatic hydrolysis, treatment with chemical reducing or oxidizing agents under mild conditions, treatment with a transition metal catalyst and a nucleophile and catalytic hydrogenation.
  • carboxyl protecting groups R 5 include allyl, benzhydryl, 2-naphthylmethyl, benzyl, silyl groups such as t-butyldimethylsilyl (TBDMS), trimethylsilyl, (TMS), triethylsilyl (TES), phenacyl, p-methoxybenzyl, o-nitrobenzyl, p-methoxyphenyl, p- nitrobenzyl (pNB), 4-pyridylm ethyl and t-butyl, preferably pNB and benzyl.
  • TDMS t-butyldimethylsilyl
  • TMS trimethylsilyl
  • TES triethylsilyl
  • phenacyl p-methoxybenzyl, o-nitrobenzyl, p-methoxyphenyl, p- nitrobenzyl (pNB), 4-pyridylm ethyl and t-but
  • suitable alcohol protecting groups R 1 include hydrogen, trialkylsilyl, diarylalkylsilyl, aryldialkylsilyl or trityl such as TMS, TES, TBDMS, alkyl carbonates such as benzyl carbonate, allyl carbonate, benzyl ether, diarylalkylsilyl, aryldialkylsilyl & trityl and the like.
  • Preferred R 1 groups are trialkylsilyl or hydrogen.
  • R 1 represents H or a suitable protecting group for an alcohol
  • R 2 represents a benzyl, C ⁇ alkyl or aryl
  • Y represents C ⁇ 3 alkyl, O, NH or S
  • X represents O, NH, or S
  • R 5 represents a carboxy protecting group, comprising reacting a compound of formula 2:
  • R 1 represents H or a suitable protecting group for an alcohol
  • R 2 represents a benzyl, C ⁇ .6 alkyl or aryl
  • Y represents C l 3 alkyl, O, NH or S
  • X represents O, NH, or S
  • R 5 represents a carboxy protecting group, comprising reacting a compound of formula 5:
  • R 1 , R 2 , R 5 , X and Y are as previously described with a phosphite or phosphonite reagent to produce a compound of formula 6.
  • R 1 represents H or a suitable protecting group for an alcohol
  • R 2 represents a benzyl, C ⁇ alkyl or aryl
  • Y represents C ⁇ g alkyl, O, NH or S
  • X represents O, NH, or S
  • R 5 represents a carboxy protecting group, comprising reacting a compound of formula 2:
  • R 1 represents H or a suitable protecting group for an alcohol
  • R 2 represents a benzyl, C ⁇ alkyl or aryl
  • Y represents C ⁇ g alkyl, O, NH or S
  • X represents O, NH, or S
  • R 5 represents a carboxy protecting group, comprising reacting a compound of formula 1:
  • R 1 is described above and R 4 represents C ⁇ alkyl, aryl or C ⁇ _ 6 aralkyl; with a compound of formula 3:
  • R 2 , X and Y are as previously defined in the presence of WZ 4 and an amine to produce a compound of formula 2:
  • W is a titanium, zirconium or hafnium metal and Z represents halo, sulfonate, alkoxy, aryloxy or combination thereof, and Rl, R2, X and Y are as previously described, reacting a compound of formula 2 with an activated oxalic acid agent in the presence of a base to produce a compound of formula 5 HoC
  • R 1 represents H or a suitable protecting group for an alcohol
  • R 2 represents a benzyl, C ⁇ g alkyl or aryl
  • Y represents C ⁇ g alkyl, O, NH or S
  • X represents O, NH, or S
  • R 5 represents a carboxy protecting group, comprising reacting a compound of formula 1:
  • R 1 is described above and R 4 represents C 1 . 15 alkyl, aryl or C 1 6 ar alkyl; with a compound of formula 3:
  • R 2 , X and Y are as previously defined in the presence of WZ 4 and an amine to produce a compound of formula 2:
  • W is a titanium, zirconium or hafnium metal and Z represents halo, sulfonate, alkoxy, aryloxy or combination thereof, and Rl, R2, X and Y are as previously described, and reacting a compound of formula 2 with an oxalimide forming agent in the presence of a base to produce a compound of formula 5.
  • Suitable amines includes trialkylamines such as triethylamine, tributylamine, trimethylamine, ethyl dimethylamine, tri- n-propylamine, di-isopropylethylamine, aniline, N j N-di-C ⁇ g - alkylanilines such as N,N-diethylaniline and the like.
  • Suitable bases include trialkylamines such as triethylamine, trimethylamine, ethyldimethylamine, tri-n-propylamine and the like, l,8-diazabicyclo[5.4.0.]undec-7-ene (DBU), pyridine, imidazole, lutidine, collidine, 4-dimethylaminomethylpyridine, inorganic carbonates and bicarbonates such as sodium carbonate, sodium bicarbonate, potassium bicarbonate, potassium carbonate, and the like and tartrates such as potassium sodium tartrate, potassium tartrate, potassium bitartrate, sodium tartrate, sodium bitartrate and the like, preferably pyridine, lutidine or collidine.
  • DBU diazabicyclo[5.4.0.]undec-7-ene
  • Suitable phosphites include P(OR a )(OR b )(OR c ); P(OR a )(OR b )(NR c R d ); P(R a )(R b )(R c ); catechol phosphites or catechol dimer phosphites, wherein R a , R b , R c and R d may be the same or different and represent a straight or branched chain C ⁇ g alkyl or a phenyl, both of which may be optionally substituted with, for example, a C ⁇ alkyl.
  • Preferable phosphites are trialkylphosphites such as triethyl phosphite, tributyl phosphite, triisopropyl phosphite, trimethyl phosphite and the like, most preferably triethylphosphite.
  • Suitable phosphonites include P(OR e )(OR f )(R ), wherein R e and R f independently represent C 1 4 alkyl, allyl, benzyl or phenyl, optionally substituted with C ⁇ alkyl or C ⁇ alkoxy and R g presents C ⁇ alkyl, trifluoromethyl or phenyl, which is optionally substituted with C 1.3 alkyl or C 1.3 alkoxy.
  • Suitable activated oxylic acid agents include acid and carbodiimide moieties such as oxalyl chloride and benzyl oxalyl chloride.
  • R 1 represents an alcohol protecting group selected from the group consisting of: H, TES, TMS, TBDMS, pNB, p- nitrobenzyloxycarbonyl, allyl and allyloxycarbonyl.
  • R 5 represents an carboxylic acid protecting group selected from the group consisting of: p-nitrobenzyl (pNB), trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBDMS), allyl, p-methoxybenzyl, benzyl, trichloroethyl, 2- trimethylsilyl ethyl, and the like.
  • pNB p-nitrobenzyl
  • TMS trimethylsilyl
  • TES triethylsilyl
  • TDMS tert-butyldimethylsilyl
  • allyl p-methoxybenzyl, benzyl, trichloroethyl, 2- trimethylsilyl ethyl, and the like.
  • Still other processes that are of particular interest are those described above wherein Y represents O or CH 2 . Still other processes that are of particular interest are those described above wherein Y represents O.
  • Typical conditions for the reaction involve generation of the titanium, zirconium or hafnium enolate of a suitably protected derivative of 1-hydroxybutanone such as an alkyl or aryl carbonate, preferably ethyl carbonate or isobutylcarbonate. This can be achieved by the addition of the corresponding metal tetrahalide to the derivative of 1- hydroxybutanone followed by addition of a trialkylamine.
  • the stoichiometry of the enolate formation requires at about 0.5 to 3.0 equivalents, preferably 1 to 2.0 equivalents of metal tetrahalide. About 0.5 to about 5 equivalents, preferably about 1 to about 3 equivalents and most preferably about 1 to about 2.0 equivalents of trialkyl amine is used.
  • the enolate generation is generally carried out at a temperature of about -80°C to about 60°C, preferably about -40°C to about 30°C.
  • the azetidinone is added to the enolate and the reaction temperature warmed to about 0°C - 30°C.
  • the stoichiometry of the reaction requires about 1.0 to about 5 equivalents, preferably about 1 to about 2.0 equivalents of the enolate of the alkyl or aryl carbonate of 1- hydroxybutanone or its synthetic equivalent.
  • Suitable solvents for the reaction include aromatic solvents such as benzene, toluene, xylene and the like, ethereal solvents such as tetrahydrofuran (THF), diethyl ether, dioxane and the like and haloalkyl solvents such as 1,2 dichloroethane, dichloromethane, chloroform, and the like, preferably the aromatic solvents.
  • aromatic solvents such as benzene, toluene, xylene and the like
  • ethereal solvents such as tetrahydrofuran (THF), diethyl ether, dioxane and the like
  • haloalkyl solvents such as 1,2 dichloroethane, dichloromethane, chloroform, and the like, preferably the aromatic solvents.
  • the azetidinone is reacted with, for example, a titanium enolate of the ethyl or isobutyl carbonate of 1- hydroxy-2-butanone, preferably the isobutyl carbonate moiety.
  • the protecting group e.g. TBDMS
  • HF hydrofluoric acid
  • HC1 HC1
  • fluorosilicic acid H 2 SiF 6
  • another alcohol protecting group e.g. TES derivative, typically using TESC1, benzyl ethers or allyl ethers
  • a base such as imidazole or pyridine.
  • the cyclization step typically involves reacting the oxalimide in the presence of a phosphite or phosphonite reagent, preferably a trialkylphosphite agent.
  • cyclization requires from about 2 to about 6 equivalents, preferably about 2.5 to about 5 equivalents of the phosphite or phosphonite.
  • the cyclization is generally carried out at a temperature of about 25°C to about 200°C, depending on the nature of the phosphorus reagent used. When using a trialkylphosphite reagent the temperature is generally about 90°C to about 160°C.
  • the carbapenem produced in the cyclization is a key intermediate in the synthesis of anti-MRSA carbapenem antibiotics and can be readily coupled to a wide range of functional groups in via methods taught in USSN 08/825,786.
  • the final product may be characterized structurally by techniques such as NMR, IR, MS, and UV.
  • the final product if not crystalline, may be lyophilized from water to afford an amorphous, easily handled solid.
  • the compounds of the present invention are valuable intermediates for antibacterial agents that are active against various Gram-positive and to a lesser extent Gram-negative bacteria, and accordingly find utility in human and veterinary medicine.
  • MRSA/MRCNS In vitro antibacterial activity is predictive of in vivo activity when the compounds are administered to a mammal infected with a susceptible bacterial organism.
  • Titanium tetrachloride solution was added to a solution of the isobutyl carbonate in toluene at -40°C. Tributylamine was added. The acetoxy azetidinone was then added and the reaction stirred at room temperature. After 3 hours the reaction was quenched with dilute hydrochloric acid. The toluene layer was washed with dilute HCl. The toluene layer was used in the subsequent step. Isolated prod, 13C NMR (CDC13) ⁇ -5.0, -4.3, 11.7, 17.9, 18.8, 22.5, 25.8, 27.8, 44.6, 51.0, 61.7, 65.4, 69.8, 74.8, 154.8, 168.3, 205.65
  • Example 2 To the toluene solution from Example 1 was added acetonitrile and the HF solution. After 6 hours the reaction was quenched with aq. Rochelles salt. The toluene layer was dried and the solvent was removed. The crystalline product was swished with hexanes and filtered to yield 4-[3- ((l-oxy-2-oxobutane)isobutyl carbonate)] -2-azetidinone (23.3g) as a white solid.
  • Triethyl phosphite was added to a solution of TES oxalimide isobutyl carbonate in xylene. The reaction was heated to 135°C for 3 hours. The reaction was given several aqueous washes, dried and the solvent removed in vacuo to afford the desired compound (12.2g).
  • lH NMR (399.87 MHz, CDCI3) d 8.22 (m, 2 H), 7.66 (m, 2 H), 5.57 (d,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un procédé efficace de synthèse d'un composé de formule (2), consistant à faire réagir une 4-acyl-2-azétidone avec un énolate de titane, zirconium ou hafnium d'un dérivé de 1-hydroxy-2-butanone.
EP99916629A 1998-04-16 1999-04-12 Preparation de produits intermediaires des carbapenems catalysee au titane Withdrawn EP1071685A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8200398P 1998-04-16 1998-04-16
US82003P 1998-04-16
GBGB9811297.2A GB9811297D0 (en) 1998-05-26 1998-05-26 Process for the synthesis of carbapenem intermediates, and compounds produced
GB9811297 1998-05-26
US9142298P 1998-07-01 1998-07-01
US91422P 1998-07-01
PCT/US1999/007956 WO1999052908A1 (fr) 1998-04-16 1999-04-12 Preparation de produits intermediaires des carbapenems catalysee au titane

Publications (2)

Publication Number Publication Date
EP1071685A1 true EP1071685A1 (fr) 2001-01-31
EP1071685A4 EP1071685A4 (fr) 2001-07-18

Family

ID=27269329

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99916629A Withdrawn EP1071685A4 (fr) 1998-04-16 1999-04-12 Preparation de produits intermediaires des carbapenems catalysee au titane

Country Status (5)

Country Link
EP (1) EP1071685A4 (fr)
JP (1) JP2002511470A (fr)
AU (1) AU745980B2 (fr)
CA (1) CA2328219A1 (fr)
WO (1) WO1999052908A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1104424B1 (fr) 1998-06-17 2004-04-07 Merck & Co., Inc. Procede permettant la synthese d'intermediaires de carbapenems
JP2003277390A (ja) * 2002-03-25 2003-10-02 Takasago Internatl Corp アゼチジノン化合物の製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330108A1 (fr) * 1988-02-22 1989-08-30 Fujisawa Pharmaceutical Co., Ltd. Composés dérivés d'acide 3-alkényl-1-aza-bicyclo(3.2.0)hept-2-ène-2-carboxylique
EP0476649A2 (fr) * 1990-09-20 1992-03-25 Hoechst Aktiengesellschaft Procédé de préparation de dérivés de carbapénème
EP0573667A1 (fr) * 1991-12-26 1993-12-15 Nippon Soda Co., Ltd. Procede de production d'un derive d'azetidinone substitue en position 4

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756725A (en) * 1996-04-24 1998-05-26 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330108A1 (fr) * 1988-02-22 1989-08-30 Fujisawa Pharmaceutical Co., Ltd. Composés dérivés d'acide 3-alkényl-1-aza-bicyclo(3.2.0)hept-2-ène-2-carboxylique
EP0476649A2 (fr) * 1990-09-20 1992-03-25 Hoechst Aktiengesellschaft Procédé de préparation de dérivés de carbapénème
EP0573667A1 (fr) * 1991-12-26 1993-12-15 Nippon Soda Co., Ltd. Procede de production d'un derive d'azetidinone substitue en position 4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9952908A1 *

Also Published As

Publication number Publication date
JP2002511470A (ja) 2002-04-16
EP1071685A4 (fr) 2001-07-18
AU745980B2 (en) 2002-04-11
AU3490899A (en) 1999-11-01
WO1999052908A1 (fr) 1999-10-21
CA2328219A1 (fr) 1999-10-21

Similar Documents

Publication Publication Date Title
EP0176064A1 (fr) Intermédiaires pour la préparation de dérivés de 7-oxo-4-thia-1-aza-[3,2,0]heptane et de 7-oxo-4-thia-1-aza[3,2,0]hept-2-éne
US5459260A (en) Tricyclic or tetracyclic carbapenem compounds, their production and use
Shibata et al. Synthetic studies of 1-β-methylcarbapenem antibiotics
US6395894B2 (en) Process for the synthesis of carbapenem intermidiates, and compounds produced
IL97275A (en) 2-Transformed Alkyl-3-Carboxy new internal carboxes as antibiotics and a method for their production
AU745980B2 (en) Titanium catalyzed preparation of carbapenem intermediates
JPH0516433B2 (fr)
JPH0532668A (ja) 置換２−チオキソペナムおよび２−置換チオペネムの製造方法
JP2000344774A (ja) カルバペネム類の製造法
US6194568B1 (en) Process for synthesizing carbapenem intermediates
PL172378B1 (pl) Sposób wytwarzania nowych 4-podstawionych azetydynonów PL PL PL PL PL PL
HU204269B (en) Process for producing antibiotica of 1-carba-cepheme sceleton
KR100246950B1 (ko) 신규 카바페넴계 항생제 및 그의 제조방법
KR100262240B1 (ko) 3-치환된-7-옥소-1-아자비사이클로3,2,0 헵트-2-엔-2-카복실레이트 화합물 및 그의 제조방법
NO873353L (no) Fremgangsmaate for fremstilling av antibakterielle 7-okso-4-tia-1-azabicyklo(3.2.0)hept-2-en-derivater.
KR100523986B1 (ko) 내성균에 항생작용을 갖는 카바페넴 유도체 및 이의제조방법
KR100246951B1 (ko) 신규 카바페넴계 항생제 및 그의 제조방법
JP3003002B2 (ja) 三環性カルバペネム化合物
JPH0586062A (ja) 多環性カルバペネム化合物
KR100246952B1 (ko) 신규 카바페넴계 항생제
KR970011389B1 (ko) 신규 카바페넴계 항생제 및 그의 제조방법
KR100246953B1 (ko) 신규 카바페넴계 항생제
KR970011388B1 (ko) 신규 카바페넴계 항생제 및 그의 제조방법
CA1197841A (fr) Derives de 7-oxo-4-thia-1-aza[3,2,0]heptane et de 7-oxo-4-thia-1-aza[3,2,0]-hept-2-ene
JPS63188684A (ja) ７−オキソ−４−チア−１−アザビシクロ［３．２．０］ヘプト−２−エン誘導体の製造法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001116;LT PAYMENT 20001116;LV PAYMENT 20001116;MK PAYMENT 20001116;RO PAYMENT 20001116;SI PAYMENT 20001116

A4 Supplementary search report drawn up and despatched

Effective date: 20010606

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 477/14 A, 7C 07D 205/08 B

17Q First examination report despatched

Effective date: 20030327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041103